Aarey Drugs & Pharmaceuticals has announced a board meeting. The board approved the Annual Report and will hold the 36th Annual General Meeting on September 30, 2026, for e-voting. Mr. Virendra G. Bhatt was appointed as scrutinizer.
Aarey Drugs' board approved its Q1 standalone financial results. Revenue reached ₹44.63 Cr, with profit at ₹1.02 Cr for the quarter. No new fundraising was announced.
AAREY DRUGS AND PHARMACEUTICLES allotted 2.52 million equity shares (FV ₹10) upon conversion of warrants at ₹63.80 each, raising ₹12.06 Cr. This boosts paid-up capital from ₹28.35 Cr to ₹33.35 Cr, stemming from a prior preferential allotment.